CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado 2015

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

por Minor, David R., Puzanov, Igor, Callahan, Margaret K., Hug, Bruce A., Hoos, Axel
Publicado 2015

Uncovering the hidden structure of dynamic T cell composition in peripheral blood during cancer immunotherapy: a topic modeling approach

por Peng, Xiyu, Lee, Jasme, Adamow, Matthew, Maher, Colleen, Postow, Michael A., Callahan, Margaret K., Panageas, Katherine S., Shen, Ronglai
Publicado 2023

A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy

por Peng, Xiyu, Lee, Jasme, Adamow, Matthew, Maher, Colleen, Postow, Michael A., Callahan, Margaret K., Panageas, Katherine S., Shen, Ronglai
Publicado 2023

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

por Dubin, Krista, Callahan, Margaret K., Ren, Boyu, Khanin, Raya, Viale, Agnes, Ling, Lilan, No, Daniel, Gobourne, Asia, Littmann, Eric, Huttenhower, Curtis, Pamer, Eric G., Wolchok, Jedd D.
Publicado 2016

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib

por Chapman, Paul B., Klang, Mark, Postow, Michael A., Shoushtari, Alexander Noor, Sullivan, Ryan J., Wolchok, Jedd D., Merghoub, Taha, Budhu, Sadna, Wong, Phillip, Callahan, Margaret K., Zheng, Bin, Zippin, Jonathan
Publicado 2023

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management

por Girotra, Monica, Hansen, Aaron, Farooki, Azeez, Byun, David J, Min, Le, Creelan, Ben C, Callahan, Margaret K, Atkins, Michael B, Sharon, Elad, Antonia, Scott J, West, Pamela, Gravell, Amy E
Publicado 2018

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

por Page, David B., Bourla, Ariel Bulua, Daniyan, Anthony, Naidoo, Jarushka, Smith, Eric, Smith, Melody, Friedman, Claire, Khalil, Danny N., Funt, Samuel, Shoushtari, Alexander N., Overwijk, Willem W., Sharma, Padmanee, Callahan, Margaret K.
Publicado 2015

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

por Rosner, Samuel, Kwong, Erica, Shoushtari, Alexander N., Friedman, Claire F., Betof, Allison S., Brady, Mary Sue, Coit, Daniel G., Callahan, Margaret K., Wolchok, Jedd D., Chapman, Paul B., Panageas, Katherine S., Postow, Michael A.
Publicado 2018

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

por Atkinson, Thomas M, Hay, Jennifer L, Young Kim, Soo, Schofield, Elizabeth, Postow, Michael A, Momtaz, Parisa, Warner, Allison Betof, Shoushtari, Alexander N, Callahan, Margaret K, Wolchok, Jedd D, Li, Yuelin, Chapman, Paul B
Publicado 2023

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

por Postow, Michael A, Cardona, Diana M, Taube, Janis M, Anders, Robert A, Taylor, Clive R, Wolchok, Jedd D, Callahan, Margaret K, Curran, Michael A, Lesokhin, Alexander M, Grosso, Joseph F, Horak, Christine E, Cogswell, John, Simon, Jason S, Gupta, Ashok K, Sznol, Mario
Publicado 2014

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

por Sharma, Padmanee, Callahan, Margaret K, Bono, Petri, Kim, Joseph, Spiliopoulou, Pavlina, Calvo, Emiliano, Pillai, Rathi N, Ott, Patrick A, de Braud, Filippo, Morse, Michael, Le, Dung T, Jaeger, Dirk, Chan, Emily, Harbison, Chris, Lin, Chen-Sheng, Tschaika, Marina, Azrilevich, Alex, Rosenberg, Jonathan E
Publicado 2016

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade

por Boland, Julia L., Zhou, Qin, Martin, Madhuri, Callahan, Margaret K., Konner, Jason, O’Cearbhaill, Roisin E., Friedman, Claire F., Tew, William, Makker, Vicky, Grisham, Rachel N., Hensley, Martee L., Zecca, Nicholas, Iasonos, Alexia E., Snyder, Alexandra, Hyman, David M., Sabbatini, Paul, Aghajanian, Carol, Cadoo, Karen A., Zamarin, Dmitriy
Publicado 2018

Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVIT...

por Ascierto, Paolo Antonio, Lipson, Evan J., Dummer, Reinhard, Larkin, James, Long, Georgina V., Sanborn, Rachel E., Chiarion-Sileni, Vanna, Dréno, Brigitte, Dalle, Stéphane, Schadendorf, Dirk, Callahan, Margaret K., Nyakas, Marta, Atkinson, Victoria, Gomez-Roca, Carlos Alberto, Yamazaki, Naoya, Tawbi, Hussein A., Sarkis, Naomey, Warad, Deepti, Dolfi, Sonia, Mitra, Priyam, Suryawanshi, Satyendra, Grob, Jean-Jacques
Publicado 2023

Health-related quality of life results from the phase III CheckMate 067 study

por Schadendorf, Dirk, Larkin, James, Wolchok, Jedd, Hodi, F. Stephen, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher, Wagstaff, John, Callahan, Margaret K., Postow, Michael A., Smylie, Michael, Ferrucci, Pier Francesco, Dummer, Reinhard, Hill, Andrew, Taylor, Fiona, Sabater, Javier, Walker, Dana, Kotapati, Srividya, Abernethy, Amy, Long, Georgina V.
Publicado 2017

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

por Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Publicado 2013

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

por Sanborn, Rachel E, Pishvaian, Michael J, Callahan, Margaret K, Weise, Amy, Sikic, Branimir I, Rahma, Osama, Cho, Daniel C, Rizvi, Naiyer A, Sznol, Mario, Lutzky, Jose, Bauman, Julie E, Bitting, Rhonda L, Starodub, Alexander, Jimeno, Antonio, Reardon, David A, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim M, Subramaniam, Deepa S, Aragon-Ching, Jeanny B, Hawthorne, Thomas R, Rawls, Tracey, Yellin, Michael, Keler, Tibor
Publicado 2022

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

por Kluger, Harriet M., Tawbi, Hussein A., Ascierto, Maria L., Bowden, Michaela, Callahan, Margaret K., Cha, Edward, Chen, Helen X., Drake, Charles G., Feltquate, David M., Ferris, Robert L., Gulley, James L., Gupta, Shilpa, Humphrey, Rachel W., LaVallee, Theresa M., Le, Dung T., Hubbard-Lucey, Vanessa M., Papadimitrakopoulou, Vassiliki A., Postow, Michael A., Rubin, Eric H., Sharon, Elad, Taube, Janis M., Topalian, Suzanne L., Zappasodi, Roberta, Sznol, Mario, Sullivan, Ryan J.
Publicado 2020

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

por Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D.
Publicado 2022

Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

por Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D.
Publicado 2022